About us Contacts Interactions: 118 620
Drug search by name

Pembrolizumab Intravenous and Hepatic impairment

Result of checking the interaction of drug Pembrolizumab Intravenous and disease Hepatic impairment for safety when used together.

Check result:
Pembrolizumab Intravenous <> Hepatic impairment
Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Pembrolizumab can cause immune-mediated hepatitis. Based on a population pharmacokinetic analysis, no dose adjustment is recommended for patients with mild hepatic impairment. Caution is recommended when using pembrolizumab in patients with moderate or severe hepatic impairment as there is insufficient information to determine whether there are clinically important differences in the CL of pembrolizumab in these patients. Monitor patients for abnormal liver tests prior to and periodically during treatment. It is recommended to administer corticosteroids at a dose of 0.5 to 1 mg/kg/day prednisone equivalents for grade 2 hepatitis and 1 to 2 mg/kg/day prednisone equivalents for grade 3 or greater hepatitis followed by corticosteroid taper and, based on severity of liver enzyme elevations, withhold or discontinue treatment. If appropriate modify the dose according to manufacturer recommendations. Care should be taken when using pembrolizumab in patients with hepatic impairment.

Pembrolizumab Intravenous

Generic Name: pembrolizumab

Brand Name: Keytruda

Synonyms: Pembrolizumab

Interaction with food and lifestyle
Drug interactions